G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$2.97 USD
-0.24 (-7.48%)
Updated Jun 6, 2024 04:00 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 261 - 280 ( 351 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Trila''s Last Lap, Expecting NDA Submission Soon with ''21 Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
4Q19 Results; Trilaciclib Rolling NDA Submission Expected to Complete in 2Q20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
I-SPY 2 Trial Collaboration and Upcoming Milestones; Increasing PT to $82
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Trila Tapped for I-SPY 2 Trial, Small-Cell NDA on Track for Q2:20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
SABCS: Differentiation on Safety, Dosing with Encouraging Early Efficacy
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Updated Lerociclib Phase 1b/2a Data Looks Good at SABCS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
3Q19 Financials: Post-ESMO Next Up Lerociclib at SABCS
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
3Q19 Results; Trilaciclib Rolling Submission Starts This Quarter; Lerociclib Data at SABCS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2019 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Impressive Data at ESMO for Trilaciclib in TNBC and Rolling NDA Submission for SCLC Expected 4Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Trila Moving Towards Market with Q4:19 NDA Submission, Lero Data Up Next
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
EMSO 2019 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
ESMO Preview: Ramblin? on at Las Ramblas with Across the Board Data Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D